Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID‐19
2020; Wiley; Volume: 92; Issue: 11 Linguagem: Inglês
10.1002/jmv.26004
ISSN1096-9071
AutoresVui Heng Chong, Pui Lin Chong, Dhiya Metussin, Rosmonaliza Asli, Riamiza Natalie Momin, Babu Ivan Mani, Muhammad Syafiq Abdullah,
Tópico(s)Blood disorders and treatments
ResumoJournal of Medical VirologyVolume 92, Issue 11 p. 2322-2324 LETTER TO THE EDITOR Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19 Vui Heng Chong, Corresponding Author Vui Heng Chong [email protected] [email protected] orcid.org/0000-0002-2844-4872 Department of Medicine, PMMPMHAMB Hospital, Tutong, Brunei Darussalam Department of Medicine, RIPAS Hospital, Bandar Seri Begawan, Brunei Darussalam Correspondence Vui Heng Chong, Department of Medicine, PMMPMHAMB Hospital, Tutong, Brunei Darussalam. Email: [email protected]; [email protected]Search for more papers by this authorPui Lin Chong, Pui Lin Chong Department of Medicine, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this authorDhiya Metussin, Dhiya Metussin Department of Medicine, Infectious Disease Unit, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this authorRosmonaliza Asli, Rosmonaliza Asli Department of Medicine, Infectious Disease Unit, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this authorRiamiza Natalie Momin, Riamiza Natalie Momin Department of Medicine, Infectious Disease Unit, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this authorBabu Ivan Mani, Babu Ivan Mani Department of Medicine, PMMPMHAMB Hospital, Tutong, Brunei DarussalamSearch for more papers by this authorMuhammad Syafiq Abdullah, Muhammad Syafiq Abdullah Department of Medicine, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this author Vui Heng Chong, Corresponding Author Vui Heng Chong [email protected] [email protected] orcid.org/0000-0002-2844-4872 Department of Medicine, PMMPMHAMB Hospital, Tutong, Brunei Darussalam Department of Medicine, RIPAS Hospital, Bandar Seri Begawan, Brunei Darussalam Correspondence Vui Heng Chong, Department of Medicine, PMMPMHAMB Hospital, Tutong, Brunei Darussalam. Email: [email protected]; [email protected]Search for more papers by this authorPui Lin Chong, Pui Lin Chong Department of Medicine, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this authorDhiya Metussin, Dhiya Metussin Department of Medicine, Infectious Disease Unit, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this authorRosmonaliza Asli, Rosmonaliza Asli Department of Medicine, Infectious Disease Unit, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this authorRiamiza Natalie Momin, Riamiza Natalie Momin Department of Medicine, Infectious Disease Unit, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this authorBabu Ivan Mani, Babu Ivan Mani Department of Medicine, PMMPMHAMB Hospital, Tutong, Brunei DarussalamSearch for more papers by this authorMuhammad Syafiq Abdullah, Muhammad Syafiq Abdullah Department of Medicine, RIPAS Hospital, Bandar Seri Begawan, Brunei DarussalamSearch for more papers by this author First published: 13 May 2020 https://doi.org/10.1002/jmv.26004Citations: 16Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Sarma P, Kaur H, Kumar H, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis [published online ahead of print April 16, 2020]. J Med Virol. 2020. https://doi.org/10.1002/jmv.25898 10.1002/jmv.25898 PubMedWeb of Science®Google Scholar 2Jaffe S. Regulators split on antimalarials for COVID-19. Lancet. 2020; 395(10231): 1179. https://doi.org/10.1016/S0140-6736(20)30817-5 10.1016/S0140-6736(20)30817-5 CASPubMedWeb of Science®Google Scholar 3Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base [published online ahead of print April 15, 2020]. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30172-7 10.1016/S2213-2600(20)30172-7 Web of Science®Google Scholar 4Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection [published online ahead of print March 30, 2020]. Med Mal Infect. 2020. https://doi.org/10.1016/j.medmal.2020.03.006 10.1016/j.medmal.2020.03.006 Web of Science®Google Scholar 5Chorin E, Matthew D, Shulman E. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin [published online ahead of print April 03, 2020]. medrxiv. https://doi.org/10.1101/2020.04.02.20047050 Google Scholar 6Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018; 41: 919-31. 10.1007/s40264-018-0689-4 CASPubMedWeb of Science®Google Scholar 7Liu D, Li X, Zhang Y, et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Devel Ther. 2018; 12: 1685-1695. 10.2147/DDDT.S166893 CASPubMedWeb of Science®Google Scholar 8Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013; 6: 479-87. 10.1161/CIRCOUTCOMES.113.000152 PubMedWeb of Science®Google Scholar 9Tripathy JP. Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India? [published online ahead of print April 24, 2020]. J Med Virol. 2020. https://doi.org/10.1002/jmv.25933 10.1002/jmv.25933 Web of Science®Google Scholar 10Abena PM, Decloedt EH, Bottieau E, et al. Chloroquine and hydroxychloroquine for the prevention or treatment of novel coronavirus disease (COVID-19) in Africa: caution for inappropriate off-label use in healthcare settings [published online ahead of print April 22, 2020]. Am J Trop Med Hyg. 2020. https://doi.org/10.4269/ajtmh.20-0290 10.4269/ajtmh.20-0290 PubMedWeb of Science®Google Scholar 11Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic [published online ahead of print April 15, 2020]. J Med Virol. 2020. https://doi.org/10.1002/jmv.25887 10.1002/jmv.25887 Web of Science®Google Scholar Citing Literature Volume92, Issue11Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐VIINovember 2020Pages 2322-2324 ReferencesRelatedInformation
Referência(s)